Atara Biotherapeutics, Inc.
20.00%
1,712,900
1604464
046513107
Aug 14, 2025
Aug 19, 2025, 08:15 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Panacea Innovation Limited | CO | 20.00% | 1,712,900 | 0 | 1,712,900 |
| Panacea Venture Healthcare Fund II, L.P. | Partnership | 20.00% | 1,405,000 | 0 | 1,405,000 |
| Panacea Venture Healthcare Fund II GP Company, Ltd. | CO | 20.00% | 1,405,000 | 0 | 1,405,000 |
| James Huang | Individual | 20.00% | 1,712,900 | 0 | 1,712,900 |
| Panacea Opportunity Fund I, L.P. | Partnership | 4.20% | 307,900 | 0 | 307,900 |
| Panacea Opportunity Fund I GP Company, Ltd. | CO | 4.20% | 307,900 | 0 | 307,900 |
Disclosure Items (3)
Common Stock
Atara Biotherapeutics, Inc.
1280 Rancho Conejo Blvd, Thousand Oaks, CA, 91320
From July 17, 2025 through August 19, 2025, Panacea Venture Healthcare Fund II, L.P. purchased 74,335 shares of Common Stock in a series of open market transactions for aggregate cash consideration of approximately $857,000. Panacea Venture Healthcare Fund II, L.P. obtained the funds used to purchase the Common Stock through capital contributions from their partners.
The information contained on the cover pages is incorporated by reference into this Item 5. Panacea Venture Healthcare Fund II, L.P. is the record holder of 1,405,000 shares of Common Stock, and Panacea Opportunity Fund I, L.P. is the record holder of warrants to purchase 307,900 shares of Common Stock. The warrants are immediately exercisable and do not expire. No portion of the warrants beneficially owned by the Reporting Persons may be exercised to the extent that, after giving effect to the attempted exercise, the Reporting Persons would beneficially own in excess of 19.99% of the outstanding Common Stock. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. and Panacea Opportunity Fund I GP Company, Ltd., which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., respectively. As a result, Panacea Venture Healthcare Fund II GP Company, Ltd. and Panacea Opportunity Fund I GP Company, Ltd. may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., respectively. Panacea Innovation Limited and Mr. Huang may be deemed to share beneficial ownership of the securities beneficially owned by the foregoing entities, but each disclaims such beneficial ownership.
The information contained on the cover pages is incorporated by reference into this Item 5.
On July 17, 2025, Panacea Venture Healthcare Fund II, L.P. purchased 19,335 shares of Common Stock at a weighted average price of $9.6391 per share in a series of open market transactions. On August 15, 2025, Panacea Venture Healthcare Fund II, L.P. purchased 55,000 shares of Common Stock at a weighted average price of $12.1895 per share in a series of open market transactions. Except for the transactions disclosed in this Item 5(c), none of the Reporting Persons has effected any transactions in the Common Stock during the past sixty days.
None.
Not applicable